Filter Results:
(5,051)
Show Results For
- All HBS Web
(5,051)
- People (16)
- News (1,913)
- Research (2,534)
- Events (3)
- Multimedia (216)
- Faculty Publications (1,924)
Show Results For
- All HBS Web
(5,051)
- People (16)
- News (1,913)
- Research (2,534)
- Events (3)
- Multimedia (216)
- Faculty Publications (1,924)
- 21 Aug 2023
- News
You’re More Than Your Job: 3 Tips for a Healthier Work-Life Balance
- Person Page
Press / Media
By: Gary P. Pisano
Thought Leader: Gary Pisano
by Amy Bernstein, strategy+business, Summer 2007
A leading student of the biotech business describes the problems holding the industry back, and how it can overcome... View Details
- Web
Faculty & Research
increases in property assessments without any associated increases in market values or transactions. Initiatives & Projects Health Care The Health View Details
- 10 Jul 2020
- News
Sutter Health’s Request to Delay $575 Million Settlement Is Denied
- Article
Extracorporeal Membrane Oxygenation Appropriateness: An Interdisciplinary Consensus-Based Approach
By: Robert S. Kaplan, Michael Nurok, Jonathan Warsh, Todd Griner, Mayumi Kharabi, Joseph Castongia, Cali Overbeck, Lisa Krueger, Bernice Coleman, Danny Ramzy, Joshua Chung, Alice Chan, Eric Ley, Sindhu Kubendran, Neil Parrish, Zhe Yu, Michael Landberg, Stuart Finder, Bradley T. Rosen, Harry Sax and Francisco Arabia
We describe a quality improvement initiative aimed at achieving interdisciplinary consensus about the appropriate delivery of extracorporeal membrane oxygenation (ECMO). Interdisciplinary rounds were implemented for all patients on ECMO and addressed whether care was... View Details
Kaplan, Robert S., Michael Nurok, Jonathan Warsh, Todd Griner, Mayumi Kharabi, Joseph Castongia, Cali Overbeck, Lisa Krueger, Bernice Coleman, Danny Ramzy, Joshua Chung, Alice Chan, Eric Ley, Sindhu Kubendran, Neil Parrish, Zhe Yu, Michael Landberg, Stuart Finder, Bradley T. Rosen, Harry Sax, and Francisco Arabia. "Extracorporeal Membrane Oxygenation Appropriateness: An Interdisciplinary Consensus-Based Approach." Anesthesia & Analgesia 128, no. 3 (March 2019).
- August 2008 (Revised September 2008)
- Case
The Flaxil Label (A)
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Disorders; Product Launch; Negotiation Process; Business and Government Relations; Safety; Pharmaceutical Industry
Barron, Greg M. "The Flaxil Label (A)." Harvard Business School Case 909-001, August 2008. (Revised September 2008.)
- 02 Sep 2020
- News
How to Launch a New Biosciences Product: Start Small or Dive in?
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- Web
Institute For Strategy And Competitiveness
1 | January 2021 To compete successfully in an increasingly value-oriented marketplace, health care providers must adopt a strategic Value Agenda that delivers outcomes that... View Details
- Article
Resilience vs. Vulnerability: Psychological Safety and Reporting of Near Misses with Varying Proximity to Harm in Radiation Oncology
By: Palak Kundu, Olivia Jung, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg and Ann Raldow
Background
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details
Kundu, Palak, Olivia Jung, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg, and Ann Raldow. "Resilience vs. Vulnerability: Psychological Safety and Reporting of Near Misses with Varying Proximity to Harm in Radiation Oncology." Joint Commission Journal on Quality and Patient Safety 47, no. 1 (January 2021): 15–22.
- 21 Apr 2009
- First Look
First Look: April 21, 2009
distinguishing between direct and complementary spillovers, we examine (1) the extent to which a hospital's specialization in areas related to cardiovascular care directly impacts performance in cardiovascular View Details
Keywords: Martha Lagace
- November 2022
- Case
Ajax Health: A New Model for Medical Technology Innovation
By: Regina E. Herzlinger and Ben Creo
This case teaches key success factors for both startup and established MedTech firms. It examines how to structure a firm to maximize innovation and financial returns with organizational structures that better align the incentives for the different skill sets... View Details
Keywords: Business Startups; Success; Innovation Strategy; Mergers and Acquisitions; Market Entry and Exit; Financial Strategy; Business Model; Partners and Partnerships; Entrepreneurship; Private Equity; Technology Industry; Medical Devices and Supplies Industry
Herzlinger, Regina E., and Ben Creo. "Ajax Health: A New Model for Medical Technology Innovation." Harvard Business School Case 323-043, November 2022.
- 22 Sep 2016
- News
The Road to Successful Bundled Payment Risk
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)
- 06 Nov 2013
- News
Six Ways to Save Obamacare
- March 2018 (Revised January 2019)
- Case
Gilead Mexico
By: Michael Chu and V. Kasturi Rangan
With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of... View Details
Chu, Michael, and V. Kasturi Rangan. "Gilead Mexico." Harvard Business School Case 318-111, March 2018. (Revised January 2019.)
- 08 Jun 2020
- News